Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm
NCT07410494
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors (SELECT-CAR-NK)
A Phase 1/2, Open-Label, Biomarker-Driven Study of Allogeneic Donor-Derived CAR-NK Cells With Antigen Selection by Tissue Biopsy and/or Liquid Biopsy Profiling in Participants With Relapsed/Refractory Advanced Solid Tumors (Single-Target vs Dual-Target Strategy)
Sponsor: Essen Biotech
Conditions
Acute Myeloid Leukemia (AML) Breast Cancer Cancer Colorectal Cancer (Locally Advanced or Metastatic) Glioblastoma Liver Cancer Melanoma (Skin Cancer) Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma Non Hodgkin Lymphoma Non-Small Cell Lung Cancer (NSCLC) Ovarian Cancer Pancreatic Ductal Adenocarcinoma (PDAC) Prostate Cancer - Recurrent
Updated 1 time since 2026 Last updated: Feb 14, 2026 Started: Feb 1, 2026 Primary completion: Dec 28, 2027 Completion: Dec 28, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07410494, this PHASE1/PHASE2 trial focuses on Acute Myeloid Leukemia (AML) and Breast Cancer and remains actively recruiting participants. Sponsored by Essen Biotech, it has been updated 1 time since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
1 version recorded Recruiting — PHASE1/PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Essen Biotech
Data source: Essen Biotech
For direct contact, visit the study record on ClinicalTrials.gov .